X-Waiver No Longer Required to Treat Opioid Use Disorder

In DEA guidance released in Jan 2023, an X-Waiver is no longer required to treat patients with buprenorphine for opioid use disorder. ACEP has more details about treatment options and training requir...

EM Opioid Advisory Network

COMPASS Huntington: A Unique First Responder Wellness Center

Fentanyl and Induction in the age of Fentanyl


Buprenorphine after Naloxone

Passing the Time After Opioid Stuffing in Asymptomatic Adults

6 Part Webinar Series on Opioid Use Disorder, Federal and State Regulations, Regulatory Considerations, and State Initiatives


ACEP Hosts Summit on Impact of Stigma and OUD in Emergency Settings

Join Our Interest List

Accreditation Levels

Frequently Asked Questions

Pain and Addiction Care in the ED

Sex-Based Differences in Opioid-Induced Respiratory Depression

Bills in the House & Senate to “Deregulate” Buprenorphine and Other Legislative & Regulatory News

PDMP Legislation

Naloxone Legislation

Pain Management

Continuing Medical Education

State Specific Policies

Myths and Facts of Opioid Policy Advocacy

Opioid Prescribing Legislation

Opioid Advocacy Resources

You’ve Got a Friend: Eva’s Village Opioid Overdose Recovery Program and Peer Recovery Specialists

Update on ACEP’s Opioid Advocacy Efforts

Opioids Reference Materials for ED Staff

Opioids - Patient Education Handouts

Opioid Use Disorder Resources

Opioid Prescribing in the ED

Sobering Centers

Senate Approves ACEP-Supported Opioid Legislation

Drug Take Back Programs

Electronic Prescription Drug Monitoring Programs

Opioid Resources